FDA approves a new weight loss drug, Zepbound from Eli Lilly
The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
Weight Loss
How weight loss drugs may impact spending
The popularity of like Ozempic and Wegovy for weight loss may already be impacting consumption habits by helping consumers suppress their appetite. CBS MoneyWatch reporter Megan Cerullo reports the hunger suppressors also have the potential to boost demand for healthier foods and activities like going to the gym.
Ozempic, Wegovy may cause stomach problems
Popular weight loss drugs Ozempic and Wegovy have been linked to an increased risk of severe stomach problems, including pancreatitis and stomach paralysis. CBS News' Elaine Quijano reports on the new JAMA study.
Is your Ozempic pen fake? Group warns of counterfeit weight loss drugs
The warning about scams comes as sales have boomed for Ozempic, Wegovy and other drugs used for weight loss.
FDA updates Ozempic label with potential blocked intestines side effect
The FDA stopped short of saying the potentially life-threatening condition was caused by the drugs, which have become popular for weight loss.
Are morning workouts better for weight loss?
Medical weight loss physician Dr. Sue Decotiis told CBS News that the best exercise is whatever fits your schedule.
Weight-loss drugs may raise risk of complications under anesthesia
Experts say the drugs can slow digestion so much that it puts patients at increased risk for a problem called pulmonary aspiration, which can cause dangerous lung damage, infections and even death.
Wegovy cuts risks of serious heart problems, new study shows
The risk of heart attack, stroke and cardiovascular death dropped significantly in patients that took the new weight-loss drug over a five-year period.
Wegovy may cut cardiovascular risk
The maker of diabetes and weight loss medication Wegovy said a trial found that the drug can also cut the risk of cardiovascular disease by 20%.
Study: Wegovy cuts heart attack, stroke risk
A new study shows the popular weight loss drug Wegovy can also reduce the risk of a heart attack or stroke by 20%. That's according to a not yet peer-reviewed clinical trial performed by drugmaker Novo Nordisk that studied more than 17,000 non-diabetic adults with heart disease who were obese or overweight. Cardiologist Dr. Ernst von Schwarz joins CBS News to discuss the significance of the findings.
Ozempic, Mounjaro makers sued over "stomach paralysis" claims
A personal injury law firm filed a suit against Novo Nordisk and Eli Lilly and Co., the manufacturers of Ozempic and Mounjaro.
Weight loss drug makers facing lawsuit
The makers of Ozempic and Mounjaro, drugs used for both weight loss and diabetes management, are facing a lawsuit claiming the medications can cause "stomach paralysis." Janet Shamlian reports.
Weight loss drugs and mental health
The European Medicines Agency is broadening its investigation into a class of popular weight loss and diabetes drugs after patients in Iceland reported thoughts of self-harm and suicide after taking Ozempic and Saxenda. Dr. Celine Gounder. editor-at-large for public health at KFF Health News and a CBS News medical contributor, has more.
Ozempic side effects could lead to hospitalization; long-term impacts unknown
Shedding pounds isn't the only change patients might experience.
The safety and promise of new weight loss drugs
The drug used in Ozempic, Wegovy and other groundbreaking medications could soon be available in pill form if the FDA approves. Dr. Celine Gounder, a CBS News medical contributor and editor-at-large for public health at KFF Health News, has more on how these drugs work and how safe they are.
Ozempic, Wegovy may soon be available in pill form
Ozempic and Wegovy, the injectable diabetes medications that are also being used for weight loss, may soon be available in pill form. Drugmaker Novo Nordisk said it will seek approval for the pills later this year.
Drugs with weight loss side effects in demand
Medications that have a side effect of weight loss have seen a recent influx of popularity. Some manufacturers say they're having difficulty keeping up with increased demand as the medications become more normalized as a way to lose weight even though that's not the primary purpose for them. Dr. Lisa Palmer, a psychotherapist and founder of the Renew Center of Florida, joined CBS News to talk about the risks.
What to know about berberine, the trending weight loss supplement
Berberine is the latest supplement craze, gaining attention on social media as a "natural" weight loss option. Here's what to know, according to experts.
FDA issues warning about weight loss drugs
The FDA issued a new warning about some of the popular diabetes drugs being used for weight loss after the agency "received adverse event reports after patients used compounded semaglutide." That's the generic name for medications like Ozempic and Wegovy. New York endocrinologist Dr. Florence Comite joins CBS News to discuss the risks of taking off-brand versions.
Are you taking part in "ambition sizing"? Here's how to judge
Ambition sizing is drastic weight loss tied to a specific event - and it can be more harmful than you think. Here's why.
Jenny Craig plans to close its weight-loss centers, report says
Employees are losing their jobs as weight-loss company's plans to wind down its brick-and-mortar business.
Eli Lilly seeks FDA approval for weight loss drug
Pharmaceutical giant Eli Lilly is requesting fast-track approval from the Food and Drug Administration for its Type 2 diabetes medication tirzepatide to be sold as a weight loss drug. The company said that new studies have shown promising results. Nikki Battiste has more.
Social media fuels enthusiasm for new weight loss drugs
The new medications show promise for inducing weight loss, but many aren't FDA-approved for that use.
Ozempic-like drug Wegovy coming to the U.K. at a fraction of U.S. price
The maker of semaglutide tells CBS News it has ramped up production "24-hours, seven days a week" to meet expected demand in new markets.
Half of world will be overweight or obese by 2035, report finds
The report from the World Obesity Federation also predicts childhood obesity could more than double compared to 2020 levels.
As Trump plans autism announcement, Tylenol maker and medical experts push back
Ahead of an expected announcement from the Trump administration linking Tylenol to autism risk, the drugmaker and medical experts are pushing back on the claims.
The night Jeffrey Epstein claimed his cellmate tried to kill him
New internal documents reveal details of an incident that left Jeffrey Epstein injured and on suicide watch days before his death.
White House shares plan to "save" TikTok, says Beijing agrees
"We feel confident that China has approved the deal," a senior White House official told reporters.
Sarah Ferguson dropped by U.K. charities over reported Epstein email
Newspapers in the U.K. published an email that Prince Andrew's ex-wife Sarah Ferguson reportedly wrote to the late convicted sex offender Jeffrey Epstein.
Parents navigate mixed messaging on child vaccine recommendations
Parents are navigating mixed messaging about childhood vaccinations from federal and state officials.
4 soldiers killed in Black Hawk helicopter crash identified by Army
Andrew Cully, Andrew Kraus, Donavon Scott and Jadalyn Good were part an elite team that does nighttime missions.
Maps show the forecast track of Hurricane Gabrielle
After growing into a hurricane, Gabrielle, the seventh named storm of the 2025 Atlantic hurricane season, is gaining steam, but is not expected to make landfall.
Bankrupt Spirit Airlines is furloughing one-third of its flight attendants
Spirit Airlines to furlough 1,800 flight attendants as budget carrier restructures, looks to cut costs.
Mamdani cancels appearance in WABC-TV town hall after Jimmy Kimmel suspension
Zohran Mamdani, the Democratic frontrunner in the race for New York City mayor, is pulling out of an upcoming town hall on WABC-TV.